amlodipine has been researched along with Cardiac Failure in 102 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to test the hypothesis of whether amlodipine reduces the risk for death in patients with heart failure due to a nonischemic cardiomyopathy." | 9.17 | Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). ( Anderson, SA; Carson, P; DeMets, DL; Elkayam, U; Konstam, MA; Moe, G; O'Connor, C; Packer, M; Rouleau, JL; Schocken, D, 2013) |
| "This prospective, randomized study assessed the safety and efficacy of metoprolol alone or combined with amlodipine on hemodynamic parameters at baseline, 2 hours after the first dose of study medication, and after 12 weeks of therapy in patients receiving background triple therapy for mild to severe heart failure." | 9.09 | Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. ( Buchholz-Varley, C; Freudenberger, RS; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, ON; Steinmetz, M, 1999) |
| "The addition of 10 mg of amlodipine per day to standard therapy in patients with heart failure is associated with no significant improvement in exercise time compared with placebo therapy over a 12-week period, and there was no increased incidence of adverse events." | 9.09 | Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. ( Berk, M; DeAbate, CA; Gorwitt, J; Konstam, MA; Kukin, ML; LeJemtel, T; Levine, TB; Neuberg, G; Packer, M; Smith, WB; Udelson, JE; Vijay, NK, 2000) |
| "We randomly assigned 1153 patients with severe chronic heart failure and ejection fractions of less than 30 percent to double-blind treatment with either placebo (582 patients) or amlodipine (571 patients) for 6 to 33 months, while their usual therapy was continued." | 9.08 | Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. ( Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, D; Ghali, JK; Miller, AB; Neuberg, GW; O'Connor, CM; Packer, M; Pressler, ML; Wertheimer, JH, 1996) |
| "To assess the effect of short-term amlodipine therapy on baseline measures of sympathetic activity and baroreflex function in patients with chronic stable congestive heart failure (CHF)." | 9.08 | Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure. ( Goldsmith, SR, 1997) |
| "We sought to determine whether the beneficial effects of amlodipine in heart failure may be mediated by a reduction in tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels." | 9.08 | Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. ( Bowers, JA; Cropp, AB; Ghali, JK; Mohler, ER; Pressler, ML; Schocken, DD; Sorensen, LC; Willis, PW, 1997) |
| "To observe the effect of amlodipine besylate combined with metoprolol in treating hypertension and heart failure." | 8.31 | Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure. ( Chen, C; Jiao, D; Shen, J; Zhang, W; Zhang, X; Zhu, G, 2023) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 7.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 7.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| "The fixed combination of perindopril arginine and amlodipine besylate ensures high therapeutic effect in patients with arterial hypertension and concomitant chronic cardiac insufficiency having signs of chronic kidney disease." | 7.81 | [EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE]. ( Borovkova, NY; Kuznetsova, TE, 2015) |
| "The EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) study was designed to evaluate the effectiveness, tolerability and adherence of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCT) single-pill combination therapies in patients with hypertension from the Middle East and Asia studied in routine clinical practice." | 7.80 | Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. ( Assaad-Khalil, SH; Cho, B; Kitchlew, AR; Knap, D; Najem, R; Shete, A; Sison, J; Ueng, KC, 2014) |
| "The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis." | 7.73 | Comparative effects of pranidipine with amlodipine in rats with heart failure. ( Aizawa, Y; Gurusamy, N; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, SS; Prakash, P; Veeraveedu, PT; Wahed, MI; Watanabe, K; Wen, J, 2006) |
| "A case of acute poisoning with amlodipine with deep hypotension, transient oliguria and clinical signs of acute heart failure was described." | 7.71 | [Deep hypotension with transient oliguria and severe heart failure in course of acute intentional poisoning with amlodipine]. ( Feldman, R; Glińska-Serwin, M, 2001) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 7.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| " This study examined whether NO is involved in the in-vivo coronary vasodilator effects of amlodipine (a calcium channel blocker) and whether heart failure (HF) alters the coronary responses to amlodipine." | 7.71 | Reduced coronary vasodilator responses to amlodipine in pacing-induced heart failure in conscious dogs: role of nitric oxide. ( Champagne, S; Crozatier, B; Héloire, F; Hittinger, L; Sambin, L; Su, JB; Suto, Y, 2002) |
| "Past studies have suggested that amlodipine, a dihydropyridine L-type Ca(2+) channel antagonist, may exert useful effects in congestive heart failure (CHF)." | 7.71 | Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility. ( Clair, MJ; Gay, DM; Goldberg, A; Hendrick, JW; Jolly, JR; King, MK; McElmurray, JH; Mukherjee, R; Patterson, TM; Spinale, FG, 2001) |
| "Amlodipine improves exercise capacity in patients with chronic congestive heart failure (HF), but the mechanisms of this effect are unknown." | 7.70 | Vascular and cardiac effects of amlodipine in acute heart failure in dogs. ( Belenkie, I; Isaac, DL; Manyari, DE; Tyberg, JV, 1998) |
| "This study examined the effects of chronic amlodipine treatment on left ventricular (LV) pump function, systemic hemodynamics, neurohormonal status, and regional blood flow distribution in an animal model of congestive heart failure (CHF) both at rest and with treadmill exercise." | 7.70 | Chronic amlodipine treatment during the development of heart failure. ( Clair, MJ; Dodd, MG; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG; Zellner, JL, 1998) |
| "In patients with congestive heart failure (CHF) receiving therapy with angiotensin-converting enzyme (ACE) inhibition, institution of calcium channel antagonism with amlodipine provided favorable effects." | 7.70 | Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure. ( Clair, MJ; Dodd, MG; Houck, WV; Kribbs, SB; Krombach, RS; Merritt, WM; Mukherjee, R; Spinale, FG, 1998) |
| "This study examined the acute effects of amlodipine treatment on left ventricular pump function, systemic hemodynamics, neurohormonal status, and regional blood flow distribution in an animal model of congestive heart failure (CHF), both at rest and with treadmill exercise." | 7.70 | Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise. ( Clair, MJ; Dodd, MG; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG, 1999) |
| "Although calcium channel blockers have not been shown to be beneficial for the treatment of patients with heart failure, a recent clinical trial demonstrated a favorable effect of amlodipine on the survival of patients with heart failure resulting from nonischemic dilated cardiomyopathy." | 7.69 | Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. ( Matsui, S; Matsumori, A; Okada, I; Sasayama, S; Sato, Y; Shioi, T; Shiota, K; Suzuki, H; Wang, WZ; Yamada, T, 1997) |
| "These included mitral regurgitation (hazard ratio [HR], 2." | 6.71 | Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. ( Anstrom, KJ; Belkin, RN; Cabell, CH; Cropp, AB; Dumesnil, JG; Jollis, JG; Miller, AB; O'Connor, CM; Ryan, T; Trichon, BH; Velazquez, EJ, 2004) |
| "In the nonischemic stratum, however, sudden deaths and pump failure deaths were reduced by 38% and 45%, respectively, with amlodipine." | 6.69 | Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. ( Anderson, S; Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, DJ; Miller, AB; Neuberg, GW; O'Connor, CM; Pressler, ML; Wertheimer, JH, 1998) |
| "The treatment with amlodipine (AMLO group) or Tempol (TEMP group) significantly inhibited the development of LV hypertrophy and cardiac dysfunction." | 5.33 | Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. ( Aburatani, H; Hasegawa, H; Kohro, T; Komuro, I; Niitsuma, Y; Takano, H; Ueda, K, 2006) |
| "40 patients with congestive heart failure (CHF) treated in the Department of Cardiology of Medical University in Wrocław participated in this study." | 5.32 | [Influence of amlodipine on serum level of some cytokines in patients with congestive heart failure]. ( Halawa, B; Karolko, B; Salomon, P, 2003) |
| "Overall, doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2." | 5.32 | Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. ( Aralica, G; Batelja, L; Blagaic, AB; Hanzevacki, JS; Konjevoda, P; Kusec, V; Lovric-Bencic, M; Rogic, D; Seiwerth, S; Sikiric, P, 2004) |
| "Heart failure was induced by rapid ventricular pacing in conscious dogs." | 5.30 | Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. ( Bernstein, R; Hintze, TH; Nasjletti, A; Recchia, FA; Xu, X; Zhang, X, 1999) |
| "This study was designed to test the hypothesis of whether amlodipine reduces the risk for death in patients with heart failure due to a nonischemic cardiomyopathy." | 5.17 | Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). ( Anderson, SA; Carson, P; DeMets, DL; Elkayam, U; Konstam, MA; Moe, G; O'Connor, C; Packer, M; Rouleau, JL; Schocken, D, 2013) |
| "The addition of 10 mg of amlodipine per day to standard therapy in patients with heart failure is associated with no significant improvement in exercise time compared with placebo therapy over a 12-week period, and there was no increased incidence of adverse events." | 5.09 | Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. ( Berk, M; DeAbate, CA; Gorwitt, J; Konstam, MA; Kukin, ML; LeJemtel, T; Levine, TB; Neuberg, G; Packer, M; Smith, WB; Udelson, JE; Vijay, NK, 2000) |
| "This prospective, randomized study assessed the safety and efficacy of metoprolol alone or combined with amlodipine on hemodynamic parameters at baseline, 2 hours after the first dose of study medication, and after 12 weeks of therapy in patients receiving background triple therapy for mild to severe heart failure." | 5.09 | Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. ( Buchholz-Varley, C; Freudenberger, RS; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, ON; Steinmetz, M, 1999) |
| "We randomly assigned 1153 patients with severe chronic heart failure and ejection fractions of less than 30 percent to double-blind treatment with either placebo (582 patients) or amlodipine (571 patients) for 6 to 33 months, while their usual therapy was continued." | 5.08 | Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. ( Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, D; Ghali, JK; Miller, AB; Neuberg, GW; O'Connor, CM; Packer, M; Pressler, ML; Wertheimer, JH, 1996) |
| "To assess the effect of short-term amlodipine therapy on baseline measures of sympathetic activity and baroreflex function in patients with chronic stable congestive heart failure (CHF)." | 5.08 | Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure. ( Goldsmith, SR, 1997) |
| "We sought to determine whether the beneficial effects of amlodipine in heart failure may be mediated by a reduction in tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels." | 5.08 | Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. ( Bowers, JA; Cropp, AB; Ghali, JK; Mohler, ER; Pressler, ML; Schocken, DD; Sorensen, LC; Willis, PW, 1997) |
| "The risk of myocardial infarction was significantly decreased with an amlodipine-based regimen compared with a non-CCB-based regimen (odds ratio [OR], 0." | 4.90 | Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. ( Choi, HM; Ko, SK; Lee, HY; Lee, SA; Park, HJ, 2014) |
| "To review the efficacy and safety data of amlodipine and the angiotensin-receptor blockers (ARBs), focusing on heart failure, angina, percutaneous coronary intervention (PCI), and renal protection." | 4.81 | Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications. ( Kalus, JS; White, CM, 2002) |
| " hypertension clinical trial databases for amlodipine (Norvasc) and nifedipine in the gastrointestinal therapeutic system (GITS) formulation (Procardia XL)." | 4.80 | Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. ( Kloner, RA; Levenstein, M; Materson, BJ; Vetrovec, GW, 1998) |
| "To observe the effect of amlodipine besylate combined with metoprolol in treating hypertension and heart failure." | 4.31 | Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure. ( Chen, C; Jiao, D; Shen, J; Zhang, W; Zhang, X; Zhu, G, 2023) |
| " amlodipine in patients with hypertension and different risks of cardiovascular events, followed for a mean of 4." | 3.88 | Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. ( Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA, 2018) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 3.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| "The fixed combination of perindopril arginine and amlodipine besylate ensures high therapeutic effect in patients with arterial hypertension and concomitant chronic cardiac insufficiency having signs of chronic kidney disease." | 3.81 | [EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE]. ( Borovkova, NY; Kuznetsova, TE, 2015) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 3.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| "The EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) study was designed to evaluate the effectiveness, tolerability and adherence of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCT) single-pill combination therapies in patients with hypertension from the Middle East and Asia studied in routine clinical practice." | 3.80 | Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. ( Assaad-Khalil, SH; Cho, B; Kitchlew, AR; Knap, D; Najem, R; Shete, A; Sison, J; Ueng, KC, 2014) |
| "ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha1-blocker (doxazosin) in preventing the new onset of heart failure (HF)." | 3.74 | The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. ( Black, HR; Cushman, WC; Davis, BR; Einhorn, PT; Levy, D; Massie, BM; Nwachuku, CE; Piller, LB; Simpson, LM, 2007) |
| "The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis." | 3.73 | Comparative effects of pranidipine with amlodipine in rats with heart failure. ( Aizawa, Y; Gurusamy, N; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, SS; Prakash, P; Veeraveedu, PT; Wahed, MI; Watanabe, K; Wen, J, 2006) |
| " This study examined whether NO is involved in the in-vivo coronary vasodilator effects of amlodipine (a calcium channel blocker) and whether heart failure (HF) alters the coronary responses to amlodipine." | 3.71 | Reduced coronary vasodilator responses to amlodipine in pacing-induced heart failure in conscious dogs: role of nitric oxide. ( Champagne, S; Crozatier, B; Héloire, F; Hittinger, L; Sambin, L; Su, JB; Suto, Y, 2002) |
| "A case of acute poisoning with amlodipine with deep hypotension, transient oliguria and clinical signs of acute heart failure was described." | 3.71 | [Deep hypotension with transient oliguria and severe heart failure in course of acute intentional poisoning with amlodipine]. ( Feldman, R; Glińska-Serwin, M, 2001) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 3.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "Past studies have suggested that amlodipine, a dihydropyridine L-type Ca(2+) channel antagonist, may exert useful effects in congestive heart failure (CHF)." | 3.71 | Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility. ( Clair, MJ; Gay, DM; Goldberg, A; Hendrick, JW; Jolly, JR; King, MK; McElmurray, JH; Mukherjee, R; Patterson, TM; Spinale, FG, 2001) |
| "In patients with congestive heart failure (CHF) receiving therapy with angiotensin-converting enzyme (ACE) inhibition, institution of calcium channel antagonism with amlodipine provided favorable effects." | 3.70 | Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure. ( Clair, MJ; Dodd, MG; Houck, WV; Kribbs, SB; Krombach, RS; Merritt, WM; Mukherjee, R; Spinale, FG, 1998) |
| "This study examined the effects of chronic amlodipine treatment on left ventricular (LV) pump function, systemic hemodynamics, neurohormonal status, and regional blood flow distribution in an animal model of congestive heart failure (CHF) both at rest and with treadmill exercise." | 3.70 | Chronic amlodipine treatment during the development of heart failure. ( Clair, MJ; Dodd, MG; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG; Zellner, JL, 1998) |
| "This study examined the acute effects of amlodipine treatment on left ventricular pump function, systemic hemodynamics, neurohormonal status, and regional blood flow distribution in an animal model of congestive heart failure (CHF), both at rest and with treadmill exercise." | 3.70 | Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise. ( Clair, MJ; Dodd, MG; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG, 1999) |
| "Amlodipine improves exercise capacity in patients with chronic congestive heart failure (HF), but the mechanisms of this effect are unknown." | 3.70 | Vascular and cardiac effects of amlodipine in acute heart failure in dogs. ( Belenkie, I; Isaac, DL; Manyari, DE; Tyberg, JV, 1998) |
| "Although calcium channel blockers have not been shown to be beneficial for the treatment of patients with heart failure, a recent clinical trial demonstrated a favorable effect of amlodipine on the survival of patients with heart failure resulting from nonischemic dilated cardiomyopathy." | 3.69 | Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. ( Matsui, S; Matsumori, A; Okada, I; Sasayama, S; Sato, Y; Shioi, T; Shiota, K; Suzuki, H; Wang, WZ; Yamada, T, 1997) |
| "2 years in the VALUE trial (Valsartan Antihypertensive Long-Term Use Evaluation)." | 2.94 | Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. ( Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB, 2020) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| " We aimed to investigate whether baseline predictors of cardiac morbidity, the major constituent of the primary endpoint in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, were different in patients with diabetes and new-onset diabetes compared to patients without diabetes." | 2.82 | Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. ( Aksnes, TA; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M, 2016) |
| "The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure." | 2.78 | Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. ( Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K, 2013) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "These included mitral regurgitation (hazard ratio [HR], 2." | 2.71 | Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. ( Anstrom, KJ; Belkin, RN; Cabell, CH; Cropp, AB; Dumesnil, JG; Jollis, JG; Miller, AB; O'Connor, CM; Ryan, T; Trichon, BH; Velazquez, EJ, 2004) |
| "In the nonischemic stratum, however, sudden deaths and pump failure deaths were reduced by 38% and 45%, respectively, with amlodipine." | 2.69 | Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. ( Anderson, S; Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, DJ; Miller, AB; Neuberg, GW; O'Connor, CM; Pressler, ML; Wertheimer, JH, 1998) |
| "Treatment with amlodipine versus placebo significantly delayed the mean (+/- SD) time to first hospitalization (447 +/- 26 d vs 315 +/- 18 d, respectively; P = 0." | 2.69 | Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. ( Martin, BC; O'Connor, CM; Radensky, PW; Unger, AN, 1999) |
| " Although the overall goal of these drugs remains the blockade of RAS activation, their individual targets in this system vary and may substantially influence the clinical benefit derived from the long term use of these substances." | 2.45 | Angiotensin II type 1 receptor blockade: high hopes sent back to reality? ( Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B, 2009) |
| "Felodipine is a highly vascular selective calcium entry blocker, with a vascular selectivity ratio greater than 100, as shown experimentally." | 2.39 | Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. ( Cheng, CP; Elvelin, L; Little, WC; Nordlander, M, 1995) |
| "amlodipine was associated with lower BPV than other CCBs for both hypertensive patients and hypertensive patients with comorbidity." | 1.48 | Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis. ( Dong, P; Li, L; Lin, Y; Liu, D; Xie, X; Yang, J; Zhang, L, 2018) |
| "Obesity is a major and independent cardiovascular risk factor." | 1.34 | [Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. ( Aguilar Llopis, A; Arístegui Urrestarazu, R; Armada Peláez, B; Cosín Aguilar, J; Hernándiz Martínez, A; Masramón Morell, X; Rodríguez Padial, L; Zamorano Gómez, JL, 2007) |
| "Heart failure was four times more frequent in these patients with renal disease than in other hypertensives." | 1.33 | [Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. ( Aguilar-Llopis, A; Arístegui-Urrestarazu, R; Cosín-Aguilar, J; Hernándiz-Martínez, A; Masramón-Morell, X; Rodríguez-Padial, L; Zamorano-Gómez, JL, 2006) |
| "The treatment with amlodipine (AMLO group) or Tempol (TEMP group) significantly inhibited the development of LV hypertrophy and cardiac dysfunction." | 1.33 | Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. ( Aburatani, H; Hasegawa, H; Kohro, T; Komuro, I; Niitsuma, Y; Takano, H; Ueda, K, 2006) |
| "40 patients with congestive heart failure (CHF) treated in the Department of Cardiology of Medical University in Wrocław participated in this study." | 1.32 | [Influence of amlodipine on serum level of some cytokines in patients with congestive heart failure]. ( Halawa, B; Karolko, B; Salomon, P, 2003) |
| "Overall, doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2." | 1.32 | Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. ( Aralica, G; Batelja, L; Blagaic, AB; Hanzevacki, JS; Konjevoda, P; Kusec, V; Lovric-Bencic, M; Rogic, D; Seiwerth, S; Sikiric, P, 2004) |
| "Both in CHF (congestive heart failure) and CRI (chronic renal insufficiency), blood pressure reduction is beneficial for preservation of cardiac and renal function." | 1.31 | Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency. ( Ikeda, N; Kanno, Y; Moriwaki, K; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H, 2002) |
| "Diastolic dysfunction and left ventricular hypertrophy are also associated with a higher risk of heart failure and systolic dysfunction." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| "Heart failure was induced by rapid ventricular pacing in conscious dogs." | 1.30 | Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. ( Bernstein, R; Hintze, TH; Nasjletti, A; Recchia, FA; Xu, X; Zhang, X, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (30.39) | 18.2507 |
| 2000's | 41 (40.20) | 29.6817 |
| 2010's | 23 (22.55) | 24.3611 |
| 2020's | 7 (6.86) | 2.80 |
| Authors | Studies |
|---|---|
| Itoga, NK | 1 |
| Tawfik, DS | 1 |
| Montez-Rath, ME | 1 |
| Chang, TI | 1 |
| Lee, HW | 1 |
| Huang, CC | 1 |
| Leu, HB | 1 |
| Lin, YJ | 1 |
| Chen, C | 1 |
| Zhang, W | 1 |
| Jiao, D | 1 |
| Shen, J | 1 |
| Zhu, G | 1 |
| Zhang, X | 3 |
| Bird, GS | 1 |
| D'Agostin, D | 1 |
| Alsanosi, S | 1 |
| Lip, S | 1 |
| Padmanabhan, S | 1 |
| Parekh, AB | 1 |
| Mehlum, MH | 2 |
| Liestøl, K | 2 |
| Kjeldsen, SE | 3 |
| Wyller, TB | 1 |
| Julius, S | 4 |
| Rothwell, PM | 2 |
| Mancia, G | 3 |
| Parati, G | 2 |
| Weber, MA | 2 |
| Berge, E | 2 |
| Khayyat-Kholghi, M | 1 |
| Oparil, S | 4 |
| Davis, BR | 10 |
| Tereshchenko, LG | 2 |
| Ostroumova, OD | 1 |
| Kochetkov, AI | 1 |
| Arablincky, NA | 1 |
| Shatalova, NA | 1 |
| Romanovsky, RR | 1 |
| Kirichenko, AA | 1 |
| Hua, TA | 2 |
| Zhang, L | 1 |
| Yang, J | 1 |
| Li, L | 1 |
| Liu, D | 1 |
| Xie, X | 1 |
| Dong, P | 1 |
| Lin, Y | 1 |
| Haywood, LJ | 3 |
| Piller, LB | 4 |
| Simpson, LM | 3 |
| Ghosh, A | 1 |
| Einhorn, PT | 3 |
| Ford, CE | 6 |
| Probstfield, JL | 2 |
| Soliman, EZ | 1 |
| Wright, JT | 3 |
| Johnson, K | 1 |
| Cushman, WC | 4 |
| Furberg, CD | 2 |
| Habib, GB | 1 |
| Margolis, K | 1 |
| Whelton, PK | 2 |
| Yamashita, K | 1 |
| Kondo, T | 1 |
| Muramatsu, T | 1 |
| Matsushita, K | 1 |
| Nagahiro, T | 1 |
| Maeda, K | 1 |
| Shintani, S | 1 |
| Murohara, T | 1 |
| Packer, M | 6 |
| Carson, P | 1 |
| Elkayam, U | 1 |
| Konstam, MA | 2 |
| Moe, G | 1 |
| O'Connor, C | 1 |
| Rouleau, JL | 3 |
| Schocken, D | 1 |
| Anderson, SA | 1 |
| DeMets, DL | 3 |
| Pfeffer, MA | 1 |
| Skali, H | 1 |
| Park, CG | 1 |
| Lee, SA | 1 |
| Choi, HM | 1 |
| Park, HJ | 1 |
| Ko, SK | 1 |
| Lee, HY | 1 |
| Sison, J | 1 |
| Assaad-Khalil, SH | 1 |
| Najem, R | 1 |
| Kitchlew, AR | 1 |
| Cho, B | 1 |
| Ueng, KC | 1 |
| Shete, A | 1 |
| Knap, D | 1 |
| Kuznetsova, TE | 1 |
| Borovkova, NY | 1 |
| Borovkova, NJ | 1 |
| Kuznecova, TE | 1 |
| Borovkov, NN | 1 |
| Kovaleva, GV | 1 |
| Aksnes, TA | 1 |
| Rostrup, M | 1 |
| Holzhauer, B | 1 |
| Kanorskii, SG | 1 |
| Sereda, AF | 1 |
| Little, WC | 3 |
| Kostis, JB | 1 |
| Black, HR | 2 |
| Farber, MA | 1 |
| Levy, D | 2 |
| Massie, BM | 2 |
| Nawaz, S | 1 |
| Grothusen, A | 1 |
| Divchev, D | 1 |
| Luchtefeld, M | 1 |
| Schieffer, B | 1 |
| Chapman, RH | 1 |
| Yeaw, J | 1 |
| Roberts, CS | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Breitung, K | 1 |
| Remmerbach, TW | 1 |
| Takano, H | 2 |
| Hasegawa, H | 2 |
| Narumi, H | 1 |
| Shindo, S | 1 |
| Mizuma, H | 1 |
| Kuwabara, Y | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 2 |
| Lynch, AI | 1 |
| Boerwinkle, E | 1 |
| Eckfeldt, JH | 1 |
| Leiendecker-Foster, C | 1 |
| Arnett, DK | 1 |
| Rahman, M | 1 |
| Cutler, JA | 3 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Fishbane, S | 1 |
| Shah, HH | 1 |
| Kataria, A | 1 |
| Shirazian, S | 1 |
| Agarwal, R | 1 |
| Proschan, M | 2 |
| Graumlich, JF | 1 |
| Pavlik, V | 1 |
| Alderman, MH | 1 |
| Gordon, D | 1 |
| Franklin, SS | 1 |
| Blumenthal, SS | 1 |
| Castaldo, RS | 1 |
| Preston, RA | 1 |
| Kalus, JS | 1 |
| White, CM | 2 |
| Turchetti, V | 1 |
| Bellini, MA | 1 |
| Boschi, L | 1 |
| Postorino, G | 1 |
| Pallassini, A | 1 |
| Richichi, MG | 1 |
| Trabalzini, L | 1 |
| Guerrini, M | 1 |
| Forconi, S | 1 |
| Weinberg, EO | 1 |
| Shimpo, M | 1 |
| Hurwitz, S | 1 |
| Tominaga, S | 1 |
| Lee, RT | 1 |
| Mozaffarian, D | 2 |
| Nye, R | 2 |
| Levy, WC | 2 |
| Salomon, P | 1 |
| Halawa, B | 1 |
| Karolko, B | 1 |
| Wijeysundera, HC | 1 |
| Hansen, MS | 1 |
| Stanton, E | 1 |
| Cropp, AS | 1 |
| Hall, C | 1 |
| Dhalla, NS | 1 |
| Ghali, J | 1 |
| Düsing, R | 1 |
| Cabell, CH | 1 |
| Trichon, BH | 1 |
| Velazquez, EJ | 1 |
| Dumesnil, JG | 1 |
| Anstrom, KJ | 1 |
| Ryan, T | 1 |
| Miller, AB | 6 |
| Belkin, RN | 4 |
| Cropp, AB | 5 |
| O'Connor, CM | 6 |
| Jollis, JG | 1 |
| Ohbayashi, Y | 1 |
| Tsutamoto, T | 1 |
| Sakaguchi, T | 1 |
| Tanaka, T | 1 |
| Kanamori, T | 1 |
| Yokohama, H | 1 |
| Sichiri, G | 1 |
| Hukai, D | 1 |
| Okabayashi, T | 1 |
| Ozawa, T | 1 |
| Ishii, C | 1 |
| Tsutsui, T | 1 |
| Ohno, K | 1 |
| Ohnishi, M | 1 |
| Wada, A | 1 |
| Lovric-Bencic, M | 1 |
| Sikiric, P | 1 |
| Hanzevacki, JS | 1 |
| Seiwerth, S | 1 |
| Rogic, D | 1 |
| Kusec, V | 1 |
| Aralica, G | 1 |
| Konjevoda, P | 1 |
| Batelja, L | 1 |
| Blagaic, AB | 1 |
| Veeraveedu, PT | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Gurusamy, N | 1 |
| Palaniyandi, SS | 1 |
| Wen, J | 1 |
| Prakash, P | 1 |
| Wahed, MI | 1 |
| Kamal, FA | 1 |
| Mito, S | 1 |
| Kunisaki, M | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Furberg, C | 1 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Papademetriou, V | 1 |
| Ellsworth, A | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Zanchetti, A | 1 |
| Kjeldsen, S | 1 |
| McInnes, GT | 1 |
| Hua, T | 1 |
| Weber, M | 1 |
| Laragh, JH | 1 |
| Plat, F | 1 |
| Battegay, E | 1 |
| Calvo-Vargas, C | 1 |
| Cieśliński, A | 1 |
| Degaute, JP | 1 |
| Holwerda, NJ | 1 |
| Kobalava, J | 1 |
| Pedersen, OL | 1 |
| Rudyatmoko, FP | 1 |
| Siamopoulos, KC | 1 |
| Störset, O | 1 |
| Cosín-Aguilar, J | 1 |
| Hernándiz-Martínez, A | 1 |
| Arístegui-Urrestarazu, R | 1 |
| Masramón-Morell, X | 1 |
| Aguilar-Llopis, A | 1 |
| Rodríguez-Padial, L | 1 |
| Zamorano-Gómez, JL | 1 |
| Nwachuku, CE | 1 |
| Kohro, T | 1 |
| Ueda, K | 1 |
| Niitsuma, Y | 1 |
| Aburatani, H | 1 |
| Yamamoto, K | 2 |
| Hori, M | 2 |
| Cosín Aguilar, J | 1 |
| Hernándiz Martínez, A | 1 |
| Masramón Morell, X | 1 |
| Arístegui Urrestarazu, R | 1 |
| Aguilar Llopis, A | 1 |
| Zamorano Gómez, JL | 1 |
| Armada Peláez, B | 1 |
| Rodríguez Padial, L | 1 |
| Tereshenko, SN | 1 |
| Zhirov, IV | 1 |
| Uspenskaia, OV | 1 |
| Cheng, CP | 2 |
| Steffen, HM | 1 |
| Clifton, D | 1 |
| Kisch, GL | 1 |
| Vetrovec, GW | 2 |
| Elvelin, L | 1 |
| Nordlander, M | 1 |
| Ghali, JK | 2 |
| Pressler, ML | 4 |
| Carson, PE | 3 |
| Neuberg, GW | 4 |
| Frid, D | 2 |
| Wertheimer, JH | 4 |
| Wang, WZ | 1 |
| Matsumori, A | 2 |
| Yamada, T | 1 |
| Shioi, T | 1 |
| Okada, I | 1 |
| Matsui, S | 1 |
| Sato, Y | 1 |
| Suzuki, H | 2 |
| Shiota, K | 1 |
| Sasayama, S | 1 |
| Allan, JJ | 1 |
| Mohler, ER | 1 |
| Sorensen, LC | 1 |
| Schocken, DD | 1 |
| Willis, PW | 1 |
| Bowers, JA | 1 |
| Goldsmith, SR | 1 |
| de Vries, RJ | 2 |
| Anthonio, R | 1 |
| van Veldhuisen, DJ | 2 |
| Scholtens, E | 1 |
| Buikema, H | 1 |
| van Gilst, WH | 1 |
| Walsh, JT | 1 |
| Andrews, R | 1 |
| Curtis, S | 1 |
| Evans, A | 1 |
| Cowley, AJ | 1 |
| Struthers, AD | 1 |
| Handrock, R | 1 |
| Herzig, S | 1 |
| Kribbs, SB | 3 |
| Merritt, WM | 1 |
| Clair, MJ | 4 |
| Krombach, RS | 3 |
| Houck, WV | 3 |
| Dodd, MG | 3 |
| Mukherjee, R | 4 |
| Spinale, FG | 4 |
| Kloner, RA | 1 |
| Materson, BJ | 1 |
| Levenstein, M | 1 |
| Hendrick, JW | 3 |
| Hebbar, L | 2 |
| Zellner, JL | 1 |
| Frid, DJ | 2 |
| Anderson, S | 2 |
| Isaac, DL | 1 |
| Belenkie, I | 1 |
| Manyari, DE | 1 |
| Tyberg, JV | 1 |
| Recchia, FA | 1 |
| Bernstein, R | 1 |
| Xu, X | 3 |
| Nasjletti, A | 1 |
| Hintze, TH | 4 |
| Grassi, G | 1 |
| Spaziani, D | 1 |
| Seravalle, G | 1 |
| Bertinieri, G | 1 |
| Dell'Oro, R | 1 |
| Cuspidi, C | 1 |
| Kukin, ML | 2 |
| Freudenberger, RS | 1 |
| Mannino, MM | 1 |
| Kalman, J | 1 |
| Steinmetz, M | 1 |
| Buchholz-Varley, C | 1 |
| Ocampo, ON | 1 |
| Radensky, PW | 1 |
| Unger, AN | 1 |
| Martin, BC | 1 |
| Anguita Sánchez, M | 1 |
| Dunselman, PH | 1 |
| Udelson, JE | 1 |
| DeAbate, CA | 1 |
| Berk, M | 1 |
| Neuberg, G | 1 |
| Vijay, NK | 1 |
| Gorwitt, J | 1 |
| Smith, WB | 1 |
| LeJemtel, T | 1 |
| Levine, TB | 1 |
| Mital, S | 1 |
| Loke, KE | 1 |
| Slater, JP | 1 |
| Addonizio, L | 1 |
| Gersony, WM | 1 |
| Thackray, S | 1 |
| Witte, K | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Carson, PA | 1 |
| Belkin, R | 1 |
| Cropp, A | 1 |
| Sandmann, S | 1 |
| Claas, R | 1 |
| Cleutjens, JP | 1 |
| Daemen, MJ | 1 |
| Unger, T | 1 |
| Gabbarini, F | 1 |
| Adler, S | 2 |
| Huang, H | 2 |
| Loke, K | 1 |
| Laumas, A | 1 |
| McElmurray, JH | 1 |
| Patterson, TM | 1 |
| Goldberg, A | 1 |
| King, MK | 1 |
| Gay, DM | 1 |
| Jolly, JR | 1 |
| Trochu, JN | 1 |
| Gupta, S | 1 |
| Uusimaa, P | 1 |
| Tokola, H | 1 |
| Ruskoaho, H | 1 |
| Vuolteenaho, O | 1 |
| Risteli, J | 1 |
| Ylitalo, A | 1 |
| Peuhkurinen, K | 1 |
| Nishikawa, N | 1 |
| Masuyama, T | 1 |
| Sakata, Y | 1 |
| Mano, T | 1 |
| Miwa, T | 1 |
| Sugawara, M | 1 |
| Nathisuwan, S | 1 |
| Talbert, RL | 1 |
| Feldman, R | 1 |
| Glińska-Serwin, M | 1 |
| Ikeda, N | 1 |
| Moriwaki, K | 1 |
| Sugahara, S | 1 |
| Kanno, Y | 1 |
| Okada, H | 1 |
| Nakamoto, H | 1 |
| Champagne, S | 1 |
| Hittinger, L | 1 |
| Héloire, F | 1 |
| Suto, Y | 1 |
| Sambin, L | 1 |
| Crozatier, B | 1 |
| Su, JB | 1 |
| Nye, RG | 1 |
| Cheng, TO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Regional and Systemic Hemodynamic Effects of a Long-term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin[NCT00151619] | Phase 2 | 7 participants (Actual) | Interventional | 1999-02-10 | Terminated | ||
| The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension[NCT01996449] | Phase 2 | 14 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 41 |
| Eplerenone | 43.8 |
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) during arm cycling exercise (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 47 |
| Eplerenone | 51 |
14 reviews available for amlodipine and Cardiac Failure
| Article | Year |
|---|---|
A Reappraisal of the Effects of L-type Ca
Topics: Amlodipine; Antihypertensive Agents; Calcium; Calcium Channel Blockers; Dihydropyridines; Fura-2; He | 2023 |
Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chi-Square Distributi | 2014 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2009 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.
Topics: Amlodipine; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Res | 2002 |
[J-ELAN study (effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension)].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2007 |
Vascular versus myocardial effects of calcium antagonists.
Topics: Amlodipine; Animals; Dogs; Felodipine; Heart Failure; Hemodynamics; Humans; Muscle, Smooth, Vascular | 1994 |
Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Hum | 1995 |
Calcium channel blockers in left ventricular dysfunction or congestive heart failure.
Topics: Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Felodipine; Heart Failure | 1997 |
Rationalizing the heart failure trials: from theory to practice.
Topics: Adrenergic beta-Antagonists; Amiodarone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti- | 1997 |
Calcium channel blocker-induced protection against cardiovascular damage.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cardiovirus Infections; Cytokines; Diltiazem; Encepha | 1997 |
Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.
Topics: Amlodipine; Calcium Channel Blockers; Cause of Death; Cerebrovascular Disorders; Clinical Trials as | 1998 |
Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.
Topics: Amlodipine; Calcium Channel Blockers; Dihydropyridines; Exercise Test; Exercise Tolerance; Felodipin | 2000 |
A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Dose-Respo | 2002 |
33 trials available for amlodipine and Cardiac Failure
| Article | Year |
|---|---|
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pre | 2020 |
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido | 2013 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sud | 2013 |
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2).
Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathies; Chronic Disease; Double-Blind Method; Female | 2013 |
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Female; Heart Failure; | 2016 |
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Identification of serum soluble ST2 receptor as a novel heart failure biomarker.
Topics: Adolescent; Adult; Aged; Amlodipine; Atrial Natriuretic Factor; Biomarkers; Calcium Channel Blockers | 2003 |
Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).
Topics: Aged; Amlodipine; Anemia; Calcium Channel Blockers; Cause of Death; Cohort Studies; Female; Follow-U | 2003 |
Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine.
Topics: Amlodipine; Calcium Channel Blockers; Catecholamines; Female; Heart Failure; Humans; Male; Middle Ag | 2003 |
Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study.
Topics: Amlodipine; Blood Flow Velocity; Double-Blind Method; Dyspnea; Echocardiography; Female; Heart Failu | 2004 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Co | 2003 |
Statin therapy is associated with lower mortality among patients with severe heart failure.
Topics: Aged; Amlodipine; Biomarkers; Calcium Channel Blockers; Cause of Death; Cholesterol; Dose-Response R | 2004 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Female; Heart A | 2006 |
[The role of amlodipine in the treatment of chronic heart failure in women].
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chronic Disease; Drug Administr | 2007 |
[Amlodipine in heart failure: initial results of the PRAISE study].
Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathy, Dilated; Coronary Disease; Double-Blind Method | 1995 |
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Cardiomyopathy, Dilated; Chronic Disease; Double-Blind M | 1996 |
Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation.
Topics: Aged; Amlodipine; Analysis of Variance; Calcium Channel Blockers; Enzyme-Linked Immunosorbent Assay; | 1997 |
Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure.
Topics: Aged; Amlodipine; Baroreflex; Blood Pressure; Calcium Channel Blockers; Cardiotonic Agents; Chronic | 1997 |
Effects of amlodipine in patients with chronic heart failure.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Chronic Disease; Double-Blind Method; Exercise Test; Exe | 1997 |
Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation.
Topics: Amlodipine; Calcium Channel Blockers; Cause of Death; Death, Sudden; Death, Sudden, Cardiac; Double- | 1998 |
Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Calcium Channel Blockers; Drug Therapy, Combination; | 1999 |
Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study.
Topics: Amlodipine; Calcium Channel Blockers; Double-Blind Method; Female; Heart Failure; Hospitalization; H | 1999 |
Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Double-Blind Method; Exercise Test; Exercise Tolerance; | 2000 |
[Calcium antagonist in heart failure. No improvement, no damage].
Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathy, Dilated; Heart Failure; Humans; Survival Rate; | 2000 |
Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme | 2000 |
Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Circadian Rhythm; Death, Sudde | 2000 |
Diuretic resistance predicts mortality in patients with advanced heart failure.
Topics: Aged; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; D | 2002 |
55 other studies available for amlodipine and Cardiac Failure
| Article | Year |
|---|---|
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chlorthalid | 2021 |
Comparative efficacy of generic nifedipine versus brand-name amlodipine for hypertension management in Taiwan.
Topics: Amlodipine; Calcium Channel Blockers; Drugs, Generic; Heart Failure; Humans; Hypertension; Ischemic | 2022 |
Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure.
Topics: Amlodipine; Heart Failure; Hemodynamics; Humans; Hypertension; Metoprolol | 2023 |
Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Heart Failure; Humans; Hyper | 2021 |
[What do we Mean by "Ideal" Blood Pressure Control?]
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hyper | 2021 |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertensi | 2018 |
Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; China; Cohort S | 2018 |
PRAISE (prospective randomized amlodipine survival evaluation) and criticism.
Topics: Amlodipine; Calcium Channel Blockers; Female; Heart Failure; Humans; Male | 2013 |
Is amlodipine more cardioprotective than other antihypertensive drug classes?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Heart Failure; Humans | 2014 |
Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Asia; Bloo | 2014 |
[EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Femal | 2015 |
[Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinat | 2015 |
[Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease].
Topics: Aged; Amlodipine; Antihypertensive Agents; Echocardiography; Exercise Tolerance; Female; Heart Failu | 2016 |
Hypertension, heart failure, and ejection fraction.
Topics: Amlodipine; Calcium Channel Blockers; Heart Failure; Humans; Hypertension; Hypolipidemic Agents; Myo | 2008 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort | 2010 |
[Gingival hyperplasia as side effect of the calcium channel blocker amlodipine].
Topics: Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Gingival H | 2010 |
Subgroup analyses in nephrology clinical trials.
Topics: Amlodipine; Data Interpretation, Statistical; Heart Failure; Humans; Nephrology; Randomized Controll | 2012 |
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Biostatistics; Blood Pressure; Cardiovascular Diseases; Chlorth | 2013 |
Haemorheological and endothelial-dependent alterations in heart failure after ACE inhibitor, calcium antagonist and beta blocker.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arginine; B | 2002 |
[Influence of amlodipine on serum level of some cytokines in patients with congestive heart failure].
Topics: Aged; Amlodipine; Calcium Channel Blockers; Endothelin-1; Female; Heart Failure; Humans; Interleukin | 2003 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.
Topics: Amlodipine; Animals; Doxorubicin; Endothelin-1; Gastric Mucosa; Heart Failure; Losartan; Male; Mice; | 2004 |
Comparative effects of pranidipine with amlodipine in rats with heart failure.
Topics: Administration, Oral; Amlodipine; Animals; Atrial Natriuretic Factor; Blood Pressure; Calcium Channe | 2006 |
[Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease].
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Di | 2006 |
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Echocardiography; Gene Expression; Heart Failure; Mal | 2006 |
[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study].
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers | 2007 |
Amlodipine story not finished yet.
Topics: Amlodipine; Drug Labeling; Heart Failure; Humans; United States; United States Food and Drug Adminis | 1994 |
Amlodipine story not finished yet.
Topics: Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Drug Labeling; Heart Failure; Humans | 1994 |
Hemodynamic and electrophysiologic effects of first- and second-generation calcium antagonists.
Topics: Amlodipine; Calcium Channel Blockers; Cardiac Output; Dihydropyridines; Electrophysiology; Female; H | 1994 |
Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production.
Topics: Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Cardiovirus Infections; Disease Models, | 1997 |
Amlodipine in chronic heart failure.
Topics: Amlodipine; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dru | 1997 |
Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Disease Models, Ani | 1997 |
[Amlodipine].
Topics: Amlodipine; Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; He | 1998 |
Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiac Paci | 1998 |
Chronic amlodipine treatment during the development of heart failure.
Topics: Amlodipine; Animals; Coronary Circulation; Exercise Test; Heart Failure; Hemodynamics; Hormones; Myo | 1998 |
Vascular and cardiac effects of amlodipine in acute heart failure in dogs.
Topics: Acute Disease; Amlodipine; Analysis of Variance; Animals; Calcium Channel Blockers; Cardiovascular S | 1998 |
Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin Receptor Antagonists; Coro | 1999 |
Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure.
Topics: Amlodipine; Antihypertensive Agents; Baroreflex; Blood Pressure; Heart Failure; Heart Rate; Humans; | 1999 |
Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Heart Failure; Humans; Randomized Con | 1999 |
Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise.
Topics: Amlodipine; Animals; Confounding Factors, Epidemiologic; Coronary Circulation; Disease Models, Anima | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors | 1999 |
Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Heart Failure; Hemodynamics; Hypertrophy, Left Ventri | 2001 |
Adult congenital heart disease: Holme's heart and heart failure. Two years of treatment with amlodipine.
Topics: Amlodipine; Calcium Channel Blockers; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged | 2000 |
Modulation of renal oxygen consumption by nitric oxide is impaired after development of congestive heart failure in dogs.
Topics: Amlodipine; Animals; Bradykinin; Cardiac Pacing, Artificial; Dogs; Female; Heart Failure; Kidney; Ni | 2001 |
Comparison of amlodipine or nifedipine treatment with developing congestive heart failure: effects on myocyte contractility.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Disease Models, Animal; Heart Failure; Male; Microsco | 2001 |
Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Dogs; Endothelium, Vascul | 2001 |
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Bendroflumethiazide; Cardi | 2001 |
Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats.
Topics: Amlodipine; Analysis of Variance; Animals; Antihypertensive Agents; Calcium Channel Blockers; Collag | 2001 |
[Innovation, step innovation, Me too. Are calcium antagonists interchangeable?].
Topics: Aged; Amlodipine; Calcium Channel Blockers; Delayed-Action Preparations; Heart Failure; Humans; Hype | 2001 |
[Deep hypotension with transient oliguria and severe heart failure in course of acute intentional poisoning with amlodipine].
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Drug Overdose; Female; Heart F | 2001 |
Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Crea | 2002 |
Reduced coronary vasodilator responses to amlodipine in pacing-induced heart failure in conscious dogs: role of nitric oxide.
Topics: Amlodipine; Animals; Cardiac Pacing, Artificial; Coronary Circulation; Coronary Vessels; Dogs; Dose- | 2002 |
All calcium channel blockers are not alike.
Topics: Amlodipine; Calcium Channel Blockers; Diltiazem; Felodipine; Heart Failure; Humans; Nifedipine | 1991 |